Skip to main content
Log in

The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells

Breast Cancer Aims and scope Submit manuscript

Cite this article

Abstract

Background

We evaluated the expression of aldehyde dehydrogenase 1 (ALDH1) between primary breast lesions and pulmonary metastatic (PM) lesions in breast cancer patients.

Methods

We retrospectively analyzed the clinicopathological features and the expression statuses of ER, PR, HER2, Ki-67 and ALDH-1 in both primary and metastatic breast cancer lesions and evaluated the discordance rates in the expressions of these markers between the primary and metastatic lesions, and also the prognostic value of these factors.

Results

None of the PM patients had metastases at any other sites, and all had undergone curative breast cancer surgery. The pulmonary operation was partial resection in 15 (88 %) patients and lobectomy in 2 (12 %) patients. The median overall survival (OS) after resection of the PNs (OS) was 48 months. The discordance rates in the expressions of ER, PR, HER2, Ki67 and ALDH-1 between the primary and metastatic lesions were 0, 29, 21, 43 and 50 %, respectively.

Conclusion

There was significant discordance in the biomarkers between the primary tumors and the metastatic lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763–9.

    Article  PubMed  CAS  Google Scholar 

  2. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20:1499–504.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2011;13:17–25.

    Article  PubMed  Google Scholar 

  5. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–41.

    Article  PubMed  CAS  Google Scholar 

  7. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA. 2006;103:11707–12.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Nogami N, Shien T, Tanaka T, Nishiyama K, Mizoo T, Iwamoto T, et al. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases. Breast Cancer. 2012. [Epub ahead of print].

  9. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22:335–44.

    Article  PubMed  Google Scholar 

  11. Higaki K, Otani S, Kochi M. Pulmonary resection for metastatic breast cancer may result in a survival benefit in selected cases. Breast. 2011;20:S77.

    Article  Google Scholar 

  12. Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol. 2003;29:532–5.

    Article  PubMed  CAS  Google Scholar 

  13. Planchard D, Soria JC, Michiels S, Grunenwald D, Validire P, Caliandro R, et al. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer. 2004;100:28–35.

    Article  PubMed  Google Scholar 

  14. Tanaka F, Li M, Hanaoka N, Bando T, Fukuse T, Hasegawa S, et al. Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg. 2005;79:1711–4 (discussion 1714–5).

    Google Scholar 

  15. Casey JJ, Stempel BG, Scanlon EF, Fry WA. The solitary pulmonary nodule in the patient with breast cancer. Surgery. 1984;96:801–5.

    PubMed  CAS  Google Scholar 

  16. Bathe OF, Kaklamanos IG, Moffat FL, Boggs J, Franceschi D, Livingstone AS. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol. 1999;8:35–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

All authors have no employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, or grants or other funding to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tomohiro Nogami.

About this article

Cite this article

Nogami, T., Shien, T., Tanaka, T. et al. The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells. Breast Cancer 21, 698–702 (2014). https://doi.org/10.1007/s12282-013-0445-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-013-0445-7

Keywords

Navigation